Novartis AG (NVSEF)

OTCMKTS · Delayed Price · Currency is USD
115.32
-0.40 (-0.34%)
Jun 4, 2025, 10:35 AM EDT
17.71%
Market Cap 226.74B
Revenue (ttm) 53.22B
Net Income (ttm) 12.86B
Shares Out n/a
EPS (ttm) 6.38
PE Ratio 17.63
Forward PE 13.89
Dividend 3.97 (3.47%)
Ex-Dividend Date Mar 11, 2025
Volume 300
Average Volume 5,226
Open 114.43
Previous Close 115.72
Day's Range 114.43 - 115.32
52-Week Range 94.70 - 123.55
Beta 0.53
RSI 64.88
Earnings Date Jul 17, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]

Sector Healthcare
Founded 1996
Employees 75,883
Stock Exchange OTCMKTS
Ticker Symbol NVSEF
Full Company Profile

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial Statements

News

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co . (NYSE: BMY) entered into a co-development and co-commercialization agreement . The pact focuses on BioNTech’s investigational bispecific an...

2 days ago - Benzinga

Novartis' Pluvicto shown to slow prostate cancer in earlier setting

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a ...

2 days ago - Reuters

Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

2 days ago - WSJ

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormon...

2 days ago - GlobeNewsWire

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019

The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s (NYSE: ALC) Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of Dry Ey...

6 days ago - Benzinga

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

7 days ago - CNBC Television

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to a...

8 days ago - GlobeNewsWire

If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)

I've added Novo Nordisk and Novartis to boost The Dividend Income Accelerator's healthcare allocation and global diversification, reducing overall risk and volatility. Both companies are attractively ...

15 days ago - Seeking Alpha

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncol...

20 days ago - GlobeNewsWire

GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion

GSK plc (NYSE: GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa . Under the agreement, GSK will pay up to $2 billion in total cash consideration. This include...

21 days ago - Benzinga

Greece needs urgent cardiovascular disease action plan, says leading health executive

Greek use of interoperable digital tools and secure data platforms such as the EHDS could boost early detection and personalised treatment, while advancing CVD care, a senior Novartis executive tells ...

21 days ago - EURACTIV.com

Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know

President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality.  Trump...

22 days ago - CNBC

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

23 days ago - CNBC Television

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...

23 days ago - Seeking Alpha

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.

23 days ago - WSJ

Novartis to keep making malaria drugs if orders dry up amid aid cuts

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters...

23 days ago - Reuters

Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.

The president says big news about drug pricing is coming next week.

25 days ago - Barrons

Pressure is still on the pharma sector, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

26 days ago - CNBC Television

China sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief

Vas Narasimhan argues potential US tariffs on pharma industry are not ‘sensible’

4 weeks ago - Financial Times

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025 , NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephien...

4 weeks ago - Benzinga

BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...

4 weeks ago - Benzinga

BioNTech says Novartis executive Zapata-Gomez to become CFO

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

4 weeks ago - Reuters

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal

4 weeks ago - GuruFocus